S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
Foot Locker Builds Up Another Head of Steam; Gains Imminent
OTCMKTS:APLIF

Appili Therapeutics (APLIF) Stock Price, News & Analysis

$0.02
0.00 (0.00%)
(As of 03/27/2024 ET)
Today's Range
$0.02
$0.02
50-Day Range
$0.02
$0.03
52-Week Range
$0.02
$0.08
Volume
N/A
Average Volume
81,108 shs
Market Capitalization
$2.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
APLIF stock logo

About Appili Therapeutics Stock (OTCMKTS:APLIF)

Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in the infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of an antibiotic, metronidazole; ATI-1801, a novel topical formulation of paromomycin for the treatment of cutaneous leishmaniasis; and ATI-1701 is a live-attenuated vaccine for Francisella tularensis. Appili Therapeutics Inc. was incorporated in 2015 and is headquartered in Halifax, Canada.

APLIF Stock Price History

APLIF Stock News Headlines

Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Appili Therapeutics reports Q3 results
Appili Therapeutics Inc Ordinary Shares
Central Banks Preparing for US Dollar Collapse?
China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.
Appili Therapeutics GAAP EPS of -C$0.01
APLIF: FDA Approves LIKMEZ™ (ATI-1501)…
Appili Therapeutics Says FDA Approves LIKMEZ Metronidazole Oral Suspension
Appili Therapeutics GAAP EPS of -C$0.08
See More Headlines
Receive APLIF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Appili Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/13/2024
Today
3/29/2024
Fiscal Year End
3/31/2024
Next Earnings (Estimated)
6/21/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
OTCMKTS:APLIF
CIK
N/A
Fax
N/A
Employees
8
Year Founded
N/A

Profitability

Net Income
$-6,990,000.00
Net Margins
-456.86%
Pretax Margin
-452.87%

Debt

Sales & Book Value

Annual Sales
$280,000.00
Book Value
($0.05) per share

Miscellaneous

Free Float
106,908,000
Market Cap
$2.60 million
Optionable
Not Optionable
Beta
-0.30
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Donald D. Cilla Jr.
    M.B.A., Pharmd, CEO, President & Director
  • Mr. Kenneth G. Howling
    Chief Financial Officer
  • Dr. Gary S. Nabors Ph.D.
    Chief Development Officer

APLIF Stock Analysis - Frequently Asked Questions

How have APLIF shares performed in 2024?

Appili Therapeutics' stock was trading at $0.0265 on January 1st, 2024. Since then, APLIF stock has decreased by 19.2% and is now trading at $0.0214.
View the best growth stocks for 2024 here
.

Are investors shorting Appili Therapeutics?

Appili Therapeutics saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 86,900 shares, an increase of 16.5% from the February 29th total of 74,600 shares. Based on an average daily trading volume, of 272,100 shares, the short-interest ratio is currently 0.3 days.
View Appili Therapeutics' Short Interest
.

When is Appili Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, June 21st 2024.
View our APLIF earnings forecast
.

How were Appili Therapeutics' earnings last quarter?

Appili Therapeutics Inc. (OTCMKTS:APLIF) announced its quarterly earnings results on Tuesday, February, 13th. The company reported ($0.01) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.01). The firm had revenue of $0.36 million for the quarter.

How do I buy shares of Appili Therapeutics?

Shares of APLIF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:APLIF) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners